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The Pathophysiology of Tumor Lysis Syndrome in Oncology Patients
Jessica Richardson RN, BSN, PCCN
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Introduction

Signs/Symptoms

Patients with oncological conditions
are at an increased risk of developing a
wide variety of complications from
chemotherapy that they would not
otherwise be exposed too. One such life
threatening complication is tumor lysis
syndrome, which is an oncology
emergency that frequently lands patients
in the intensive care unit. Tumor lysis
syndrome (TLS) occurs most frequently
after the initiation of chemotherapy or
other chemotoxic drugs during the
patients’ treatment course [8]. It causes
faster than normal tumor cell breakdown
and release of intracellular contents into
the general circulation. [8]. This leads to
a very predictable development of
electrolyte imbalances to take place
within the body, which if not treated can
lead to end-organ damage as well as fatal
cardiac dysrhythmias [8]. While TLS is
fairly uncommon, there are specific
factors that place some individuals at a
higher risk of developing TLS then
others. These include large tumor size,
tumors with rapid cell division, and
hematological cancers such as leukemia
[3]. In addition, TLS can progress
extremely quickly and has a high rate of
morbidity and mortality [8]. It is
important that nurses and physicians are
educated and on the look out for TLS in
high-risk individuals and initiate
prophylactic treatment if indicated. Also,
prompt recognition of TLS and initiation
of treatment modalities is key to
preventing end-organ damage and
possibly death.
In oncology specific intensive care
units, such as the medical intensive care
unit at The James Cancer Hospital in
Columbus, Ohio, TLS is one of the most
common reasons for patients to receive
continuous renal replacement therapy
(CRRT) after sepsis. The purpose of this
poster is to provide information to
nurses on general oncology floors so that
they are able to recognize the signs and
symptoms of TLS early, in the hopes that
early identification and treatment will
improve patient outcomes and decrease
the number of patients with acute kidney
injuries necessitating the need for CRRT.

TLS is a rapidly developing
oncological emergency characterized by
a number of metabolic abnormalities
including, hyperuricemia,
hyperphosphatemia, hyperkalemia, and
hypocalcemia [2]. TLS is asymptomatic
initially, but has the ability to affect the
renal, gastrointestinal, cardiac, and
neuromuscular systems [10].
Hyperuricemia contributes to the
development of acute renal failure. Signs
and symptoms include [6]:
•
Flank pain
•
Gross hematuria
•
Cloudy urine
•
Oliguria
•
Lethergy
Hyperkalemia and hypocalcemia may
cause gastrointestinal complications
such as [6]:
•
Nausea
•
Vomiting
•
Diarrhea
•
Intestinal cramping
Hyperkalemia will cause
electrocardiogram (ECG) and
neuromuscular changes these include
[6]:
•
Atrial tachycardia
•
Irregular heart rhythms
•
Life-threatening arrhythmias
•
Neuromuscular irritability
•
Muscle weakness
•
Paralysis
Hypocalcemia also affects the
neuromuscular system and can
manifest as [6]:
•
Neuromuscular excitability
•
Seizures
•
Tetany

Pathophysiologic
Process of TLS
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Pathophysiology
TLS occurs as the result of tumor cell
breakdown, usually after exposure to
chemotherapy or chemotoxic drugs.
When cancer cells are destroyed they
release massive amounts of intracellular
contents into the extracellular space,
which cause characteristic electrolyte
abnormalities such as: hyperuricemia,
hyperphosphatemia, hyperkalemia, and
hypocalcaemia [2]. These imbalances
occur in part due to the fact that cancer
cells have an abnormally high amount of
potassium, phosphorus, and nucleic acid
contained within the cell [6].
Hyperkalemia and hyperphosphatemia
normally results 12-24 hours after
chemotherapy is initiated [8].
Hyperkalemia results from the high levels
of potassium that spills into the
extracellular space from the lysed
malignant cells, as well as from a
disruption in the sodium/potassium
adenosine triphosphatase pump which
lowers the threshold for potassium
exchange into the extracellular space [8].
This potentiates the effects of
hyperkalemia by causing additional
potassium to leak from uninjured
cancerous cells into the extracellular
space even before cell lysis has occurred
[8]. Hypocalcemia results when
extracellular calcium binds to the
elevated phosphorus circulating in the
bloodstream, which in turn leads to
decreased serum calcium [6].
Hyperuricemia generally occurs 4872 hours after initiation of treatment as
the liver converts the excess nucleic acids
into uric acid [8]. Under normal
circumstances small amounts of uric acid
are excreted by the kidneys, while the
majority of uric acid is reused by the
body through the salvage pathways [8].
Initially, the kidneys will try to
compensate for the excess uric acid in the
blood stream by increasing urine output,
but as intravascular fluid volume is
depleted uric acid crystals build up in the
renal tubules causing intrarenal
crystallization [8]. Uric acid also disrupts
the renin-angiotensin aldosterone system
by causing renal vasoconstriction,
impaired auto-regulation, decreased
renal blood flow, oxidation, and
inflammation [4]. These electrolyte
abnormalities produce clinical toxic
effects which may include renal
insufficiency, cardiac dysrhythmias,
seizures, and multi-organ failure leading
to death if not treated [4].

Significance of Pathophysiology
Understanding the pathophysiology of
TLS allows practitioners to put measures
in place to prevent complications
associated with cancer treatments in
moderate to high risk individuals. All
patients who are high risk should
receive intravenous hydration beginning
2 days before treatment and continuing
for 2-3 days after chemotherapy [3].
Fluids are administered at a rate of 2 to
3L/day with a goal urine output of 100200 mL/hour [8]. This helps maintain
renal perfusion and minimize uric acid
crystal formation in renal tubules [4].
Nurses should pay particular attention
to urine output; if output remains low
despite aggressive fluids then loop
diuretics are recommended to achieve
target urine output [4].

However, while allopurinol prevents
the formation of new uric acid from
forming, existing uric acid in the body must
still be excreted [8]. It may take the body
up to two days to decrease pre-existing uric
acid levels, which may be enough time to
cause nephropathy in some individuals [4].
In addition, xanthine, the end byproduct of allopurinol, may accumulate in
the renal tubules causing xanthine
nephropathy [4]. In contrast, Urate oxidase
(rasburicase) works by breaking down uric
acid into a more soluble compound the
body can execrate called allantoin[4]. This
prevents the formation of xanthine and
secondary accumulation in the renal
tubules and decreases the risk of
nephropathy [4].

Signs and Symptoms of Tumor Lysis Syndrome
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Patients should also be pre-treated
with allopurinol or rasburicase therapy.
Both therapies aim to control uric acid
levels by interfering with purine
catabolism, in an effort to prevent uric
acid crystal formation in the renal tubules
and preserve kidney function [8].
Allopurinol is a pharmacological
medication that works by inhibiting the
enzyme xanthine oxidase, which blocks
the conversion of enzymes that form uric
acid [5].

However, the uricase enzyme that breaks
down uric acid in rasburicase is not
normally found in humans. Administration
of rasburicase in patients has been known
to cause allergic reactions, at times leading
to anaphylaxis [8]. In addition, high costs to
institutions and lack of insurance coverage
limits the use of rasburicase in practice [8].
Patients who have a pre-existing uric acid
level of >7.5mg/dL would benefit most from
rasburicase therapy and should be
considered for use in contrast to allopurinol
[8].

Significance Cont.

Implications for Nursing

Management of other dangerous
electrolyte abnormalities is important as
well, specifically hyperkalemia, which can
cause lethal cardiac dysrhythmias if left
untreated. Administration of 50%
dextrose in water and 10 units of regular
insulin IV should be given for immediate
treatment for potassium levels > 6mEq
[8]. This shifts excess potassium into the
intracellular space. For milder cases and
longer term control sodium polystyrene
sulfonate (kayexalate) can be given to
help bind with excess potassium in the
gut as well as loop diuretics to promote
excretion of potassium through the
kidneys[8].
It is also important to treat high
phosphorus levels in the blood. If
phosphorus levels are above 7mg/dL
then 20% dextrose in water should be
given with insulin [8]. Once phosphorus
levels fall below 7mg/dL then oral
phosphate binder such as aluminum
hydroxide may be given, which works by
binding with free phosphate in the
intestines to prevent absorption [8]. If
phosphorus levels are corrected then
hypocalcemia should inversely correct
itself. Correcting hypocalcemia is
discouraged as it can potentiate the
development of calcium deposits in
tissues [8]. Replacement should only be
given to individuals who are experiencing
signs and symptoms of neuromuscular
excitability [8].
Despite prophylactic treatment many
patients’ kidneys may not be able to keep
up with the increased workload
demanded of them. Dialysis should be
considered in patients exhibiting
symptoms of oliguria, fluid overload, or
signs and symptoms related to abnormal
electrolyte levels [8]. Intermittent
dialysis or continuous renal replacement
therapy (CRRT) may be used to help filter
the blood and remove excess byproducts.
Generally, CRRT is recommended in
patients with TLS because the filters use
larger bore sizes, which allows for more
rapid clearance of molecules, in
particular it is more effective in removing
phosphorus from the blood and does not
have the rebound effect of hyperkalemia
that conventional intermittent dialysis
does [4]. The goal of dialysis therapy is to
correct the underlying electrolyte
imbalances and restore renal function.

The key in TLS is to recognize
which patients are at risk and
implementing preventative measures
before the initiation of therapy [10].
Patients at highest risk of developing TLS
include [10]
•
Those with rapidly multiplying
malignant cells
•
The elderly
•
Those dehydrated at the start of
therapy
•
Those with pre-existing renal
disease
However, any patient receiving
oncological therapies may develop TLS.
Nurses administering chemotherapy
should be knowledgeable about key
abnormal laboratory values and clinical
symptoms of:
•
Hyperkalemia
•
Hyperphosphatemia
•
Hypocalcemia
Those at high risk should be placed
on continuous cardiac monitoring [4].
Electrolytes, renal function, and uric acid
should be measured every 4-6 hours for
high-risk individuals, and every 8-12
hours for those at intermediate to low
risk [4]. Recognizing signs and
symptoms of acute renal failure is of
paramount importance as escalation of
treatment modalities may be necessary
and life saving in these individuals.
Practitioners should be on the look out
for signs of
[8]:
•
Oliguria,
•
Fluid overload
•
Hypertension
•
Pulmonary edema
In addition, blood urea nitrogen (BUN)
and creatinine should be monitored
daily[8].
Patient and family education is also
important. Patients should be educated
about complications of chemotherapy
and TLS if they are at risk. It is important
for the nurse to review home
medications, especially if the patient is
pre-medicating at home with allopurinol
or rasburicase before treatment.
Information of correct medication
administration may be key in preventing
complications associated with TLS.
Keeping the patient and family informed
also allows the patients’ and family
members to feel more in control and take
a more active role in their treatment.

Conclusion
TLS is an oncological emergency and
a major cause of morbidity and mortality
in cancer patients in the United States
and worldwide [1]. TLS causes cell lysis
and the release of massive amounts of
potassium, phosphate, and nucleic acid
into the general circulation [5]. This
causes characteristic electrolyte
abnormalities within the blood that
leads to impaired renal function, cardiac
dysrhythmias, end-organ failure, and
death if not treated [5]. The key to
managing TLS is prevention, along with
prompt recognition of symptoms,
immediate intervention, and escalation
of care when necessary
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